ObsEva SA (NASDAQ:OBSV) is scheduled to be issuing its quarterly earnings data before the market opens on Tuesday, November 14th. Analysts expect the company to announce earnings of ($0.58) per share for the quarter.
ObsEva SA (NASDAQ:OBSV) last announced its quarterly earnings results on Tuesday, August 15th. The company reported ($0.61) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.48) by ($0.13). During the same quarter in the previous year, the company posted ($0.30) earnings per share. On average, analysts expect ObsEva SA to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.
Shares of ObsEva SA (NASDAQ OBSV) opened at $11.80 on Friday. ObsEva SA has a 52-week low of $5.00 and a 52-week high of $14.69.
Several research analysts recently weighed in on the stock. HC Wainwright set a $27.00 price objective on shares of ObsEva SA and gave the stock a “buy” rating in a research report on Wednesday, August 16th. Leerink Swann restated an “outperform” rating and issued a $18.00 price objective on shares of ObsEva SA in a research report on Wednesday, August 16th. Zacks Investment Research upgraded shares of ObsEva SA from a “sell” rating to a “hold” rating in a research report on Wednesday, July 19th. Finally, Royal Bank of Canada restated a “buy” rating and issued a $22.00 price objective on shares of ObsEva SA in a research report on Thursday, November 2nd. Six equities research analysts have rated the stock with a buy rating, The stock presently has an average rating of “Buy” and a consensus target price of $18.83.
ObsEva SA Company Profile
Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: OBE2109 is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and blocks the endogenous GnRH from activating its pituitary receptors, which reduces estrogen production by the ovaries and leads to amenorrhea.
Receive News & Ratings for ObsEva SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ObsEva SA and related companies with MarketBeat.com's FREE daily email newsletter.